Key Highlights The U.S. could have saved $1.3 billion-$1.5 billion in the first year post-approval if launch prices for drugs matched value-based benchmarks, says the Institute for Clinical and Economic Review (ICER). Median annual net launch prices for new drugs jumped 51% from 2022 to 2024, while list prices rose 24%, underscoring rapid cost escalation across the healthcare industry. ICER’s analysis shows that Americans continue to pay substantially more for medicines than patients in other high-income nations. A new report from the Institute for Clinical and Economic Review (ICER) estimates that the United States could have saved up to $1.5…